Karyopharm Therapeutics | KPTI - Current Assets


Karyopharm Therapeutics reported $126.33M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Abbott USD 25.51B 488M Mar/2026
Amgen USD 34.96B 3.49B Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Incyte USD 6.03B 542.31M Jun/2026
J&J USD 59.77B 601M Jun/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Novartis USD 27.35B 744M Jun/2026
Novartis USD 26.61B 3.85B Mar/2026
Pfizer USD 41.36B 1.46B Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Takeda JPY 3.15T 59.77B Jun/2026
Tectonic Therapeutic USD 239.89M 17.47M Mar/2026
TG Therapeutics USD 1.15B 58.72M Jun/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Xencor USD 523.21M 40.36M Jun/2026